23 Nov 2020 07:00
23 November 2020
BEXIMCO PHARMACEUTICALS LIMITED
AGM Notification
Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that the forty-fourth Annual General Meeting of the Shareholders of Beximco Pharmaceuticals Limited will be held virtually on Saturday 19 December 2020 at 10.30 a.m. to transact the following business:
AGENDA
1. To receive, consider and adopt the Audited Financial Statements of the Company for the year ended on 30 June 2020 together with reports of the Auditors and the Directors thereon.
2. To declare 15% Cash Dividend and 10% Stock Dividend.
3. To elect Directors.
4. To approve the appointment of Independent Director.
5. To appoint Auditors for the year 2020-2021 and to fix their remuneration.
6. To appoint Corporate Governance Compliance Auditor for the year 2020-2021 and to fix remuneration.
| By order of the Board, |
| Sd/- |
|
|
| (MOHAMMAD ASAD ULLAH, FCS) |
Dated: 18 November 2020 | Executive Director & Company Secretary |
NOTES:
(1) The Shareholders whose names will appear in the Share Register of the Company or in the Depository Register on the record date (i.e. 25 November 2020) will be entitled to attend at the Annual General Meeting and to receive the dividend.
(2) A Member entitled to attend and vote at the General Meeting may appoint a Proxy to attend and vote in his/her stead. The Proxy Form, duly stamped, must be deposited at the Registered office of the Company, not later than 48 hours before the time fixed for the meeting.
For further information please visit www.beximcopharma.com or enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 586/11001, Ext.20080
Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext.20030
Jamal Ahmed Choudhury, Executive Director (A&F)
Tel: +880 2 58611001, Ext.20022
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0) 20 3368 3551 / 3555
SP Angel Corporate Finance LLP (Broker)
Vadim Alexandre / Abigail Wayne
Tel: +44 (0) 20 3470 0470
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0) 20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 4,500 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.